Boston, Massachusetts 02114

  • Osteopenia

Purpose:

Obesity is an important risk factor for osteoporosis and fractures. With the growing prevalence of obesity in the U.S., understanding the pathophysiology of bone loss in this population is of importance to public health. Growth hormone (GH) is a critical mediator of bone homeostasis and is markedly reduced in obesity. Our preliminary data suggest an important role for the GH/insulin-like growth factor 1 (IGF-1) system in the pathogenesis of bone loss in obesity. The development of novel imaging techniques provides an opportunity to investigate the effects of GH on skeletal structure and strength, which will provide insights into the pathogenesis of obesity related bone loss. Understanding the pathophysiology of bone loss in obesity may help identify new treatment targets for this important complication. The investigator hypothesizes that low-dose GH administration for 18 months will improve skeletal health.


Criteria:

Inclusion Criteria: - Ages 18-65 and generally healthy - BMI ≥ 25 kg/m2 - Bone mineral density (BMD) T score ≤ -1.0 and > -2.5 (as measured by DXA) Exclusion Criteria: - For women: amenorrhea for 3 months, pregnancy or breastfeeding, polycystic ovary syndrome - History of diabetes mellitus, cancer or other serious chronic disease - Use of osteoporosis medications - Anemia


NCT ID:

NCT01724489


Primary Contact:

Principal Investigator
Karen Miller, MD
Massachusetts General Hospital


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02114
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 21, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.